Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626580 | 1.00 | MAPK1 (0.42) | MAPK1GPR119JAK2JAK1USP30 | |
| SCHEMBL19616881 | 1.00 | MAPK1 (0.42) | MAPK1GPR119JAK2JAK1USP30 | |
| SCHEMBL31071410 | 0.90 | MAPK1 (0.40) | MAPK1GPR119JAK2JAK1USP30 | |
| SCHEMBL30927563 | 0.90 | MAPK1 (0.40) | MAPK1GPR119JAK2JAK1USP30 | |
| SCHEMBL19617349 | 0.90 | MAPK1 (0.40) | MAPK1GPR119JAK2JAK1USP30 | |
| SCHEMBL21328369 | 0.89 | CA1 (0.37) | — | |
| SCHEMBL26139450 | 0.82 | KDM4E (0.51) | GPR119JAK2JAK1USP30KDM4E | |
| SCHEMBL15645152 | 0.81 | LTA4H (0.46) | MAPK1GPR119JAK2JAK1USP30 | |
| SCHEMBL13705091 | 0.81 | LTA4H (0.46) | MAPK1GPR119JAK2JAK1USP30 | |
| SCHEMBL3493648 | 0.81 | LTA4H (0.46) | MAPK1GPR119JAK2JAK1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| CN-109963849-B | Nitrogen-containing heterocyclic compounds as FXR modulators | 和博医药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MAPK1 310/4885GPR119 1237/4885JAK2 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.